In vivo , the enriched immunoreactivity or transcription of the GLP-1R was detected in neurons of the DVC, paraventricular and posterior thalamic nuclei, various hypothalamic regions, ventral, posterodorsal and interpeduncular tegmental areas, the periaqueductal gray and superior colliculus, while medium to low levels of GLP-1Rs were found in the posterior/caudal hippocampus, the hippocampal CA1, temporal/cerebral cortex, striatum, substantia nigra (SN) [which included tyrosine hydroxylase (SN)-expressing dopaminergic neurons (Elabi et al., 2021)], locus coeruleus, preoptic area, parabrachial nuclei, lateral septum, lateral habenula
No usar en casos de anemia perniciosa o megaloblstica secundaria a deficiencia de vitamina B12 sin evaluacin mdica
SUMMARY Evaluation of drug delivery systems for GLP-1 receptor agonists from injectable to advanced oral, buccal, transdermal, and intranasal formulations has resulted in significant milestones in the treatment of obesity and type 2 diabetes
Mutations in this pathway lead to uncontrolled growth and proliferation
Popular in scientific communities exploring GLP-class multi-receptor formulations
P., DAlessio, D
)
